225 related articles for article (PubMed ID: 3365060)
21. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
Yamamoto S; Hayashi N; Kometani M; Nakao K; Inukai T
Arzneimittelforschung; 1997 May; 47(5):604-12. PubMed ID: 9205773
[TBL] [Abstract][Full Text] [Related]
22. Antihypertensive effects of the novel potassium channel activator SKP-450 and its major metabolites in rats.
Shin HS; Seo HW; Oh JH; Lee BH
Arzneimittelforschung; 1998 Oct; 48(10):969-78. PubMed ID: 9825113
[TBL] [Abstract][Full Text] [Related]
23. Antihypertensive properties of the novel calcium antagonist (1S,2S)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino] ethyl]-6- fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrochloride in rat models of hypertension. Comparison with verapamil.
Hefti F; Clozel JP; Osterrieder W
Arzneimittelforschung; 1990 Apr; 40(4):417-21. PubMed ID: 2357242
[TBL] [Abstract][Full Text] [Related]
24. Hemodynamic effects of cadralazine in hexamethonium treated and non-treated anesthetized dogs.
Higashio T; Tsuji Y; Nakao K; Sakaguchi S; Tanaka M
Arzneimittelforschung; 1988 Mar; 38(3):350-8. PubMed ID: 3382459
[TBL] [Abstract][Full Text] [Related]
25. Role of brain cholinergic system in the antihypertensive effect of clonidine in different models of rat hypertension.
Squadrito F; Quattrone G; Buemi M; Frisina N; Caputi AP; Squadrito G
J Hypertens Suppl; 1985 Dec; 3(4):S97-9. PubMed ID: 3868718
[TBL] [Abstract][Full Text] [Related]
26. Antihypertensive effects of a new dihydropyridine calcium antagonist.
Kimura Y; Fukui H; Tanaka M; Okamoto M; Morino A; Miura A; Kimura K; Enomoto H
Arzneimittelforschung; 1986 Sep; 36(9):1329-35. PubMed ID: 3790182
[TBL] [Abstract][Full Text] [Related]
27. Antihypertensive effects of a novel phenylpiperazine derivative, SGB-1534, on several hypertensive models of rats.
Nabata H; Aono J; Ishizuka N; Sakai K
Arch Int Pharmacodyn Ther; 1985 Sep; 277(1):104-18. PubMed ID: 3904651
[TBL] [Abstract][Full Text] [Related]
28. Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
McTavish D; Young RA; Clissold SP
Drugs; 1990 Oct; 40(4):543-60. PubMed ID: 2083513
[TBL] [Abstract][Full Text] [Related]
29. Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker.
Buoninconti R; Motolese M
Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):613-6. PubMed ID: 2867048
[TBL] [Abstract][Full Text] [Related]
30. [Antihypertensive effect of arotinolol (S-596), a new adrenergic beta blocking agent, on experimental hypertension].
Hara Y; Nakahara H; Miyagishi A; Nakatani H
Nihon Yakurigaku Zasshi; 1983 Aug; 82(2):103-16. PubMed ID: 6198264
[TBL] [Abstract][Full Text] [Related]
31. [Acute tolerance to the hypotensive effect of pindolol in spontaneously hypertensive rats (SHR)].
Matsunaga K; Ueda M
Nihon Yakurigaku Zasshi; 1983 Oct; 82(4):259-66. PubMed ID: 6141128
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the hypotensive and diuretic effects of 1,4-dimorpholino-7-phenylpyrido[3,4]pyridazine (DS-511) and hydrochlorothiazide in Doca, renal and spontaneously hypertensive rats.
Inada Y; Nishikawa K; Nagaoka A; Kikuchi S
Arzneimittelforschung; 1977; 27(9):1663-9. PubMed ID: 579134
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the antihypertensive activity of cadralazine (ISF 2469) and dihydralazine during chronic treatment.
Strocchi E; Costa FV; Caldari R; Malini PL; Marata AM; Parini J; Ambrosioni E
Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):519-23. PubMed ID: 6642790
[TBL] [Abstract][Full Text] [Related]
34. Hypotensive and diuretic actions of diltiazem in spontaneously hypertensive and Wistar Kyoto rats.
Narita H; Nagao T; Yabana H; Yamaguchi I
J Pharmacol Exp Ther; 1983 Nov; 227(2):472-7. PubMed ID: 6631726
[TBL] [Abstract][Full Text] [Related]
35. Comparative study on acute antihypertensive effects and pharmacokinetics of nisoldipine, nifedipine, nimodipine and nicardipine administered orally to conscious renal hypertensive dogs.
Takata Y; Kato H
Arzneimittelforschung; 1986 Oct; 36(10):1464-71. PubMed ID: 3814208
[TBL] [Abstract][Full Text] [Related]
36. Renal function studies with cadralazine in conscious dogs: a comparison with hydralazine.
Ferni G; Bonardi G; Lombroso M; Semeraro C; Dorigotti L
Pharmacol Res; 1989; 21(2):211-22. PubMed ID: 2664751
[TBL] [Abstract][Full Text] [Related]
37. Antihypertensive action of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride in hypertensive rat models.
Tanaka M; Yamamoto S; Nakao K; Inukai T; Ogawa N; Katsumura H; Ohara N; Shukunobe K; Ono H
Arzneimittelforschung; 1991 Jun; 41(6):608-12. PubMed ID: 1930348
[TBL] [Abstract][Full Text] [Related]
38. Antihypertensive effects of a new transdermal delivery system for clonidine (M-5041T) in spontaneously hypertensive rats.
Ishii R; Naruse T; Tagawa T; Yamahata T; Dote S; Hamada K; Ishida T; Funabiki K; Namba K
Arch Int Pharmacodyn Ther; 1994; 327(3):294-308. PubMed ID: 7848013
[TBL] [Abstract][Full Text] [Related]
39. General pharmacology of the novel centrally acting antihypertensive agent moxonidine.
Armah BI; Hofferber E; Stenzel W
Arzneimittelforschung; 1988 Oct; 38(10):1426-34. PubMed ID: 3196383
[TBL] [Abstract][Full Text] [Related]
40. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
Aono J; Koga T; Yamazaki T; Shiraki Y; Sakai K
Arch Int Pharmacodyn Ther; 1988; 292():203-22. PubMed ID: 3293542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
